Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06992583 | Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer | PHASE1 | RECRUITING | 60 | — | — | May 8, 2025 | Apr 30, 2028 | May 28, 2025 | 1 | China |
| NCT06945523 | Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer | PHASE1 | RECRUITING | 60 | — | — | Apr 28, 2025 | Apr 30, 2028 | Jun 4, 2025 | 1 | China |
| NCT06903117 | Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma | PHASE1 | RECRUITING | 60 | — | — | Mar 24, 2025 | Mar 31, 2028 | Apr 3, 2025 | 1 | China |
| NCT06768151 | A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer | PHASE1 | RECRUITING | 48 | — | — | Dec 12, 2024 | Dec 31, 2027 | Jan 10, 2025 | 1 | China |
Adverse events and their proportion during the trial (assessed against the Common Terminology Standard for Adverse Events Version 5.0 (CTCAE 5.0) and ASTCT standards)
| Arm | Type | Description |
|---|---|---|
| Targeted CEA CAR-T intravenous infusion group | EXPERIMENTAL | - |
| Targeting CEA CAR-T pleural infusion group | EXPERIMENTAL | - |
| Targeted CEA CAR-T intravenous infusion | EXPERIMENTAL | - |
| Targeting CEA CAR-T intraperitoneal infusion group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Targeted CEA CAR-T | BIOLOGICAL | Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest |
Inclusion Criteria: \- Participants must meet all of the following criteria to be eligible for enrollment: 1. Age ≥18 years, regardless of gender. 2. Histologically or cytologically confirmed advanced, metastatic, or recurrent lung cancer, including both non-small cell lung cancer (NSCLC) and sma...